Table 2.
Percent change in ESA dosing by hemoglobinopathy trait
| ESA Dose Change | HbAA | Any Hb Trait | HbAS | HbAC |
|---|---|---|---|---|
| Percent change in ESA dosea (95% CI) | Reference | 13.2 (5.1 to 21.9) | 13.2 (4.3 to 22.9) | 12.9 (−3.1 to 31.6) |
| P=0.001 | P=0.003 | P=0.12 | ||
| Percent change in weight-adjusted ESA doseb (95% CI) | Reference | 14.9 (6.3 to 24.2) | 15.3 (5.8 to 25.7) | 13.1 (−3.8 to 32.9) |
| P<0.001 | P=0.001 | P=0.14 |
Any Hb trait, any hemoglobinopathy trait (includes HbAS and HbAC).
a
Linear regression model adjusted for age, sex, vintage, intact parathyroid hormone, albumin, Kt/V, ferritin, transferrin saturation, access type, iron dose, missed treatments, and hospitalizations.
b
Linear regression model adjusted for sex, vintage, intact parathyroid hormone, albumin, ferritin, transferrin saturation, access type, iron dose, missed treatments, and hospitalizations; age and Kt/V are excluded from this model.